阿帕替尼联合顺铂和紫杉醇治疗驱动基因野生型晚期非鳞非小细胞肺癌的疗效观察

Efficacy of apatinib combined with cisplatin and paclitaxel in the treatment of driver gene wild-type advanced non-squamous non-small cell lung cancer

目的观察阿帕替尼联合顺铂和紫杉醇治疗驱动基因野生型晚期非鳞非小细胞肺癌的临床疗效和安全性。方法入组我院2016年3月至2018年6月收治的经病理学确诊的76例驱动基因野生型晚期非鳞非小细胞肺癌患者,采用随机数字表法均分为2组,每组38例。对照组接受顺铂和紫杉醇化疗,治疗组在对照组治疗基础上口服阿帕替尼。比较2组临床疗效、血清血管内皮生长因子(VEGF)水平、KPS评分及不良反应发生情况。结果治疗组总有效率高于对照组,差异有统计学意义(P<0.05)。2组化疗后血清VEGF水平均较化疗前低,且治疗组低于对照组,差异均有统计学意义(P均<0.05)。2组化疗后KPS水平均较化疗前高,且治疗组高于对照组,差异均有统计学意义(P均<0.05)。治疗组不良反应发生率稍高于对照组,但差异无统计学意义(P>0.05),2组不良反应均为Ⅰ、Ⅱ度。结论阿帕替尼联合顺铂和紫杉醇治疗驱动基因野生型晚期非鳞非小细胞肺癌的疗效确切,能改善患者血清VEGF水平,提高患者生活质量,且安全性较高。

Objective To observe the clinical efficacy and safety of apatinib combined with cisplatin and paclitaxel in the treatment of driver gene wild-type advanced non-squamous non-small cell lung cancer.Methods Seventy-six patients with driver gene wild-type advanced non-squamous non-small cell lung cancer in our hospital from March 2016 to June 2018 were divided into the control group and the observation group by the randomized method,with 38 patients in each group.The control group was given with cisplatin and paclitaxel,while the observation group orally took apatinib on the basis of treatment in the control group.The clinical efficacy,serum vascular endothelial growth factor(VEGF),KPS score,adverse reactions were compared between the two groups.Results The total response rate of the observation group was higher than that of the control group(P<0.05).After chemotherapy,the levels of VEGF in the two groups were lower than those before chemotherapy,and the observation group was lower than the control group(P<0.05).After chemotherapy,the KPS of the two groups were higher than those before chemotherapy,and the observation group was higher than the control group(P<0.05).There was statistical difference in the incidence of adverse reactions between the two groups(P>0.05),and all the adverse reactions wereⅠandⅡdegree.Conclusion Apatinib combined with cisplatin and paclitaxel is effective and safe in the treatment of driver gene wild-type advanced non-squamous non-small cell lung cancer,it can improve serum VEGF level and quality of life.